Other product royalty revenues — Total revenues
Incyte Other product royalty revenues — Total revenues decreased by 6.4% to $3.25M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 156.5%, from $1.27M to $3.25M. Over 2 years (FY 2023 to FY 2025), Other product royalty revenues — Total revenues shows an upward trend with a 100.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful commercialization of licensed assets by partners or the expansion of the royalty-bearing product portfolio, while a decrease may indicate declining market performance of these secondary drugs or the expiration of royalty agreements.
Detailed definition
This metric represents the total revenue generated from royalty payments associated with secondary or non-core pharmaceu...
Peer comparison
Comparable to royalty income streams reported by other biopharmaceutical firms that utilize licensing models to monetize non-core or early-stage drug candidates.
incy_segment_other_product_royalty_revenues_total_revenuesHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $491.75K | $491.75K | $491.75K | $491.75K | $548.00K | $876.00K | $414.00K | $333.00K | $1.27M | $1.29M | $1.86M | $3.47M | $3.25M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +11.4% | +59.9% | -52.7% | -19.6% | +280.2% | +1.7% | +44.1% | +87.1% | -6.4% |
| YoY Change | — | — | — | — | +11.4% | +78.1% | -15.8% | -32.3% | +131.0% | +46.9% | +348.1% | +942.0% | +156.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's other product royalty revenues — total revenues?
- Incyte (INCY) reported other product royalty revenues — total revenues of $3.25M in Q1 2026.
- How has Incyte's other product royalty revenues — total revenues changed year-over-year?
- Incyte's other product royalty revenues — total revenues increased by 156.5% year-over-year, from $1.27M to $3.25M.
- What is the long-term trend for Incyte's other product royalty revenues — total revenues?
- Over 2 years (2023 to 2025), Incyte's other product royalty revenues — total revenues has grown at a 100.1% compound annual growth rate (CAGR), from $1.97M to $7.88M.
- What does other product royalty revenues — total revenues mean?
- Total revenue earned from royalty payments on secondary or licensed pharmaceutical products.